Membranous Nephropathy

In primary disease, autoantibodies bind podocyte antigens such as the phospholipase A2 receptor. This binding contributes to subepithelial immune-deposit formation, which activates complement and disrupts podocyte function. Damage to podocytes weakens the filtration barrier, allowing increased protein passage into urine. The resulting proteinuria can become severe enough to produce nephrotic syndrome.

Subepithelial deposits form on the outer side of the glomerular filtration barrier, adjacent to podocytes. Their presence is associated with complement activation and altered podocyte function rather than simply reflecting nonspecific inflammation. This relationship helps explain why the clinical pattern centers on barrier leakiness and heavy protein loss, findings that are important when assessing disease severity.

Primary disease is associated with autoantibodies directed against podocyte antigens, whereas secondary disease may occur with infections, autoimmune disorders, malignancy, or medication exposure. This distinction matters because the underlying associated condition can influence evaluation and management. Identifying a possible secondary context therefore expands the clinical assessment beyond kidney findings alone.

Marked proteinuria and nephrotic syndrome indicate substantial disruption of the filtration barrier and are central to clinical risk assessment. Membranous nephropathy can also be complicated by thrombosis or infection, particularly in the setting of significant protein loss and nephrotic features. Monitoring therefore considers both renal findings and systemic consequences rather than proteinuria alone.

Clinical evaluation combines urine protein measurement, kidney function testing, and serology to characterize protein loss, assess renal performance, and look for disease-related immune markers. These results are interpreted together with the clinical context, including possible secondary causes. When additional confirmation or structural assessment is needed, clinicians may also use renal biopsy.

Renal biopsy can help establish the diagnosis by directly assessing kidney tissue and can support evaluation of the glomerular changes associated with immune deposits. It complements urine studies, kidney function tests, and serology rather than replacing them. Tissue findings may also contribute to risk assessment and help place the patient’s laboratory results in structural context.

Urine protein levels, kidney function, serology, and, when performed, biopsy findings help guide monitoring and treatment decisions. Management may include supportive care, immunosuppressive treatment, or both, depending on the assessed risk. Ongoing follow-up tracks remission, progression, and complications such as thrombosis or infection, allowing care to respond to changing clinical findings.